Economic analysis using base-case estimates

	Usual care	STS HM	STS HH	TM during office hours
Central estimates of HRs used as input				
Mortality HR	1.000	1.074	0.780	0.779
HF-related hospitalisation HR	1.000	1.045	0.778	0.966
All-cause hospitalisation HR	1.000	1.173	0.977	0.761
Treatment costs assumed per month (£)	27	119	179	175
Survival results (undiscounted)				
1 year (%)	72.14	71.31	77.58	77.67
5 years (%)	33.75	33.36	36.39	36.44
Life expectancy over 30 years (years)	4.71	4.66	5.05	5.05
Difference in life expectancy vs usual care (years)	0.00	−0.05	0.34	0.34
Cost results (£)				
Discounted cost of usual care	575	306	334	334
Discounted cost of treatment	0	1158	1828	1788
Discounted cost of HF-related hospitalisations	4187	4178	4285	4456
Discounted cost of other hospitalisations	3800	3928	4156	3775
Total costs	8562	9571	10,603	10,353
Difference in costs from usual care (£)				
Discounted cost of usual care	0	−269	−241	−240
Discounted cost of treatment	0	1158	1828	1788
Discounted cost of HF-related hospitalisations	0	−9	97	268
Discounted cost of other hospitalisations	0	128	356	−25
Total difference in costs	0	1009	2040	1791
Overall cost rank (1 = lowest cost)	1	2	4	3
Discounted QALY results				
QALYs with no hospitalisation decrement	2.5748	2.5465	2.7583	2.7613
HF-related hospitalisation decrement	−0.1611	−0.1608	−0.1649	−0.1715
Total discounted QALYs	2.4137	2.3857	2.5935	2.5898
Difference in QALYs from usual care				
QALYs with no hospitalisation decrement	0.0000	−0.0283	0.1835	0.1865
HF-related hospitalisation decrement	0.0000	0.0003	−0.0037	−0.0103

	Usual care	STS HM	STS HH	TM during office hours
Total difference in discounted QALYs	0.0000	−0.0280	0.1798	0.1761
Total discounted QALYs rank (1 = highest)	3	4	1	2
Probabilistic ICER vs usual care (£/QALY)		Dominated	11,349	10,167
Probabilistic sequential ICER (£/QALY)		Dominated	68,189[a]	10,167
Uncertainty analyses using net benefit at £20,000 per QALY				
Probability that strategy is most cost-effective (%)	2	18	35	44
Expected total costs from PSA (£)	8562	9571	10,603	10,353
Expected total QALYs from PSA	2.4137	2.3857	2.5935	2.5898
Expected net benefit from PSA (£)	39,711	38,143	41,267	41,443
Difference from usual care costs (£)	0	1009	2040	1791
Difference from usual care QALYs	0.0000	−0.0280	0.1798	0.1761
Difference from usual care net benefit (£)	0	−1568.71	1555	1732
Net benefit rank (1 = highest)	3	4	2	1
Overall EVPI per patient at ICER of £20,000 per QALY (£)	1401			
Population EVPI (£)	76,745,379			

a Last strategy in the cost-effectiveness frontier.

Economic analysis using data from predictive distributions

	Usual care	STS HM	STS HH	TM during office hours
Central estimates of HRs used as input				
Mortality HR	1.000	1.180	0.849	0.843
HF-related hospitalisation HR	1.000	1.063	0.790	0.982
All-cause hospitalisation HR	1.000	1.302	1.074	0.835
Treatment costs assumed per month (£)	27	119	179	175
Survival results (undiscounted)				
1 year (%)	72.14	70.31	76.50	76.66
5 years (%)	33.75	32.89	35.88	35.96
Life expectancy over 30 years (years)	4.710	4.596	4.980	4.991
Difference in life expectancy vs usual care (years)	–	−0.110	0.270	0.281
Cost results (£)				
Discounted cost of usual care	575	302	329	330
Discounted cost of treatment	0	1147	1812	1773
Discounted cost of HF-related hospitalisations	4187	4138	4237	4414

	Usual care	STS HM	STS HH	TM during office hours
Discounted cost of other hospitalisations	3800	3977	4204	3809
Total costs	8562	9564	10,582	10,326
Difference in costs from usual care (£)				
Discounted cost of usual care	0	−273	−246	−245
Discounted cost of treatment	0	1147	1812	1773
Discounted cost of HF-related hospitalisations	0	−49	50	227
Discounted cost of other hospitalisations	0	177	404	9
Total difference in costs	0	1002	2019	1764
Overall cost rank (1 = lowest cost)	1	2	4	3
Discounted QALY results				
QALYs with no hospitalisation decrement	2.5748	2.5129	2.7219	2.7275
HF-related hospitalisation decrement	−0.1611	−0.1593	−0.1631	−0.1699
Total discounted QALYs	2.4137	2.3536	2.5589	2.5576
Difference in QALYs from usual care				
QALYs with no hospitalisation decrement	0.0000	−0.0619	0.1471	0.1527
HF-related hospitalisation decrement	0.0000	0.0019	−0.0019	−0.0087
Total difference in discounted QALYs	0.0000	−0.0601	0.1452	0.1439
Total discounted QALYs rank (1 = highest)	3	4	1	2
Probabilistic ICER vs usual care (£/QALY)		Dominated	13,911	12,257
Probabilistic sequential ICER (£/QALY)		Dominated	205,182[a]	12,257
Uncertainty analyses using net benefit at £20,000 per QALY				
Probability that strategy is most cost-effective (%)	7	19	34	40
Expected total costs from PSA (£)	8562	9564	10,582	10,326
Expected total QALYs from PSA	2.4137	2.3536	2.5589	2.5576
Expected net benefit from PSA (£)	39,711	37,509	40,596	40,826
Difference from usual care costs (£)	0	1002	2019	1764
Difference from usual care QALYs	0.0000	−0.0601	0.1452	0.1439
Difference from usual care net benefit (£)	0	−2202.89	884	1114
Net benefit rank (1 = highest)	3	4	2	1
Overall EVPI per patient at ICER of £20,000 per QALY (£)	3034			
Population EVPI (£)	166,199,486			

a Last strategy in the cost-effectiveness frontier.

Economic analysis using data excluding the Home-HF study[67]

	Usual care	STS HM	STS HH	TM during office hours
Central estimates of HRs used as input				
Mortality HR	1.000	1.007	0.757	0.627
HF-related hospitalisation HR	1.000	1.042	0.766	0.872
All-cause hospitalisation HR	1.000	1.134	0.969	0.678
Treatment costs assumed per month (£)	27	119	179	175
Survival results (undiscounted)				
1 year (%)	72.14	72.25	78.14	81.54
5 years (%)	33.75	33.81	36.67	38.32
Life expectancy over 30 years (years)	4.710	4.716	5.082	5.293
Difference in life expectancy vs usual care (years)	–	0.0062	0.3720	0.5830
Cost results (£)				
Discounted cost of usual care	575	310	336	352
Discounted cost of treatment	0	1168	1835	1837
Discounted cost of HF-related hospitalisations	4187	4227	4303	4580
Discounted cost of other hospitalisations	3800	3939	4180	3895
Total costs	8562	9645	10,655	10,663
Difference in costs from usual care (£)				
Discounted cost of usual care	0	−265	−238	−223
Discounted cost of treatment	0	1168	1835	1837
Discounted cost of HF-related hospitalisations	0	40	116	392
Discounted cost of other hospitalisations	0	139	380	95
Total difference in costs	0	1082	2093	2101
Overall cost rank (1 = lowest cost)	1	2	3	4
Discounted QALY results				
QALYs with no hospitalisation decrement	2.5748	2.5782	2.7773	2.8921
HF-related hospitalisation decrement	−0.1611	−0.1627	−0.1656	−0.1762
Total discounted QALYs	2.4137	2.4155	2.6117	2.7159
Difference in QALYs from usual care				
QALYs with no hospitalisation decrement	0.0000	0.0034	0.2025	0.3173
HF-related hospitalisation decrement	0.0000	−0.0015	−0.0045	−0.0151
Total difference in discounted QALYs	0.0000	0.0019	0.1980	0.3022
Total discounted QALYs rank (1 = highest)	4	3	2	1
Probabilistic ICER vs usual care (£/QALY)		584,066	10,567	6953
Probabilistic sequential ICER (£/QALY)		Dominated	Extendedly dominated	6953[a]

	Usual care	STS HM	STS HH	TM during office hours
Uncertainty analyses using net benefit at £20,000 per QALY				
Probability that strategy is most cost-effective (%)	0	5	12	83
Expected total costs from PSA (£)	8562	9645	10,655	10,663
Expected total QALYs from PSA	2.4137	2.4155	2.6117	2.7159
Expected net benefit from PSA (£)	39,711	38,666	41,580	43,654
Difference from usual care costs (£)	0	1082	2093	2101
Difference from usual care QALYs	0.0000	0.0019	0.1980	0.3022
Difference from usual care net benefit (£)	0	−1045.41	1868	3942
Net benefit rank (1 = highest)	3	4	2	1
Overall EVPI per patient at ICER of £20,000 per QALY (£)	225			
Population EVPI (£)	12,325,275			

a   Last strategy in the cost-effectiveness frontier.

Economic analysis using data from predictive distributions excluding the Home-HF study[67]

	Usual care	STS HM	STS HH	TM during office hours
Central estimates of HRs used as input				
Mortality HR	1.000	1.032	0.776	0.642
HF-related hospitalisation HR	1.000	1.058	0.778	0.883
All-cause hospitalisation HR	1.000	1.235	1.048	0.731
Treatment costs assumed per month (£)	27	119	179	175
Survival results (undiscounted)				
1 year (%)	72.14	71.91	77.80	81.26
5 years (%)	33.75	33.65	36.50	38.19
Life expectancy over 30 years (years)	4.71	4.70	5.06	5.28
Difference in life expectancy vs usual care (years)	0.00	−0.01	0.35	0.57
Cost results (£)				
Discounted cost of usual care	575	309	335	350
Discounted cost of treatment	0	1165	1830	1833
Discounted cost of HF-related hospitalisations	4187	4223	4295	4575
Discounted cost of other hospitalisations	3800	4012	4247	3940
Total costs	8562	9708	10,707	10,698

	Usual care	STS HM	STS HH	TM during office hours
Difference in costs from usual care (£)				
Discounted cost of usual care	0	−266	−240	−224
Discounted cost of treatment	0	1165	1830	1833
Discounted cost of HF-related hospitalisations	0	36	108	387
Discounted cost of other hospitalisations	0	212	447	140
Total difference in costs	0	1146	2145	2136
Overall cost rank (1 = lowest cost)	1	2	4	3
Discounted QALY results				
QALYs with no hospitalisation decrement	2.5748	2.5669	2.7657	2.8825
HF-related hospitalisation decrement	−0.1611	−0.1625	−0.1653	−0.1760
Total discounted QALYs	2.4137	2.4044	2.6005	2.7065
Difference in QALYs from usual care				
QALYs with no hospitalisation decrement	0.0000	−0.0079	0.1909	0.3077
HF-related hospitalisation decrement	0.0000	−0.0013	−0.0042	−0.0149
Total difference in discounted QALYs	0.0000	−0.0093	0.1868	0.2928
Total discounted QALYs rank (1 = highest)	3	4	2	1
Probabilistic ICER vs usual care (£/QALY)		Dominated	11,486	7296
Probabilistic sequential ICER (£/QALY)		Dominated	Extendedly dominated	7296[a]
Uncertainty analyses using net benefit at £20,000 per QALY				
Probability that strategy is most cost-effective (%)	1	7	19	73
Expected total costs from PSA (£)	8562	9708	10,707	10,698
Expected total QALYs from PSA	2.4137	2.4044	2.6005	2.7065
Expected net benefit from PSA (£)	39,711	38,380	41,302	43,431
Difference from usual care costs (£)	0	1146	2145	2136
Difference from usual care QALYs	0.0000	−0.0093	0.1868	0.2928
Difference from usual care net benefit (£)	0	−1331.28	1590	3720
Net benefit rank (1 = highest)	3	4	2	1
Overall EVPI per patient at ICER of £20,000 per QALY (£)	693			
Population EVPI (£)	37,961,847			

a Last strategy in the cost-effectiveness frontier.